secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001193125-24-194863
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M
-----------------------------------------------------------------

- Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).
- Net loss ($552.2M) largely from $493.1M stock compensation and payroll taxes tied to IPO.
- Adjusted EBITDA ($31.2M), improved $12.7M QoQ from Q1; Non-GAAP genomics margin 49.4% (+50bps).
- FY2024 revenue guidance ~$700M (~32% growth); adjusted EBITDA guided at ~($105M), improvement of ~$50M.
- Launched MRD assays, JV with SoftBank for Japan, FDA 510(k) for ECG-AF device, CMS ADLT status for xT CDx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000119312524194863/0001193125-24-194863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000119312524194863/d878812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-194863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer